NSCLC
Clinical trials for NSCLC explained in plain language.
Never miss a new study
Get alerted when new NSCLC trials appear
Sign up with your email to follow new studies for NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Electric fields zap lung cancer in major trial
Disease control CompletedThis study tested whether adding a portable, battery-operated device to standard treatments helps people with advanced lung cancer live longer. The device, worn on the chest, delivers low-intensity electric fields (called TTFields) aimed at slowing or stopping cancer cell growth.…
Matched conditions: NSCLC
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug trial targets lung cancer in the brain
Disease control CompletedThis study tested an oral drug called furmonertinib in patients with advanced non-small cell lung cancer (NSCLC) that had spread to the brain. The goal was to see how well the drug controlled the cancer in the brain and body, and how safe it was. It specifically enrolled 24 patie…
Matched conditions: NSCLC
Phase: PHASE2 • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for tough cancers: testing a Triple-Threat treatment
Disease control CompletedThis study tested a new three-drug combination (afuresertib, sintilimab, and chemotherapy) for people with advanced solid tumors that had stopped responding to prior immunotherapy. The goal was to find a safe, effective dose and see if this combination could help control cancer g…
Matched conditions: NSCLC
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Blood test guides precision strikes against lingering lung cancer
Disease control CompletedThis study tested a new strategy for controlling advanced lung cancer that has spread. It aimed to see if using a sensitive blood test to detect tiny amounts of leftover cancer could guide doctors to use targeted radiation or surgery on the remaining tumors. The goal was to see i…
Matched conditions: NSCLC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug tested for Tough-to-Treat cancers
Disease control CompletedThis study tested a new drug, CFT1946, for people with advanced solid tumors that have a specific genetic change called BRAF V600. The main goals were to find a safe dose and see if the drug, given alone or with other medications, could help control the cancer. It involved 89 adu…
Matched conditions: NSCLC
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug combo tested to control advanced lung cancer
Disease control CompletedThis study tested whether adding the drug bevacizumab to standard treatment (erlotinib) works better for controlling advanced lung cancer in Chinese patients with specific genetic mutations. The trial involved 311 adults with advanced non-small cell lung cancer who had not receiv…
Matched conditions: NSCLC
Phase: PHASE3 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New combo therapy tested to control aggressive lung cancer
Disease control CompletedThis study tested whether adding an experimental drug called OSI-906 to the standard drug Tarceva could better control advanced non-small cell lung cancer in patients with specific genetic mutations. It involved 88 patients who had not yet received chemotherapy for their advanced…
Matched conditions: NSCLC
Phase: PHASE2 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Cancer trial questions: can patients stop treatment after one year?
Disease control CompletedThis study aimed to find the best length of immunotherapy treatment for people with advanced cancers. It enrolled 161 patients whose cancer had remained stable after one year of treatment. Researchers randomly assigned participants to either stop their immunotherapy or continue i…
Matched conditions: NSCLC
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New pill targets 'Undruggable' cancer mutation in early human trial
Disease control CompletedThis early-stage study tested a new oral drug, JAB-21822, in adults with advanced solid tumors (like lung or colon cancer) that have a specific genetic change called KRAS G12C. The main goals were to find a safe dose and see if the drug, given alone or with another cancer drug (c…
Matched conditions: NSCLC
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Scientists develop model to personalize lung cancer treatment
Knowledge-focused CompletedThis study looked at 3000 people with advanced lung cancer to create a prediction model. Researchers analyzed medical scans, blood tests, and lung function results to predict which patients would benefit most from immunotherapy combined with chemotherapy. The model also aims to i…
Matched conditions: NSCLC
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC